It's on the expensive end if you're just looking at sales
But take into account the growth rate, cashflow breakeven, they own the IP, c.+60% PCP sales growth in just Australia with expansion beginning.
Yes, it's expensive on paper but there's little need for capital raising (though I think they will still raise at some point) which only leaves on-market buying if you're an institution or fund, with more than 1 years vision, wanting a piece
It's on the expensive end if you're just looking at...
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.015(4.62%) |
Mkt cap ! $69.16M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 34.0¢ | 33.0¢ | $65.33K | 194.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35186 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 37875 | 3 |
View Market Depth
| Last trade - 10.10am 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
33.0¢ |
Change
0.015 ( 1.54 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 33.0¢ | 33.0¢ | 5664 | ||
| Last updated 10.10am 07/06/2024 ? | |||||
| BIO (ASX) Chart |